跳至主要内容
临床试验/NCT03388788
NCT03388788进行中(未招募)早期 1 期

Circadian Mechanisms of Cardiovascular Risk in Obesity

Oregon Health and Science University2 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2018年5月1日最近更新:
适应症

试验速览

阶段
早期 1 期
状态
进行中(未招募)
入组人数
17
试验地点
2
主要终点
Blood Pressure

研究概览

简要总结

A multidisciplinary investigation examining the circadian mechanisms regulating cardiovascular (CV) risk, with an additional focus on obesity. Specifically, in a valid circadian protocol, the investigators aim to study resting cardiovascular risk markers and the reactivity of circadian rhythms in these risk markers to standardized stressors. It is intended to compare results in lean and obese individuals to determine if there are specific risks across the circadian cycle specific to obesity. Furthermore, using an exploratory approach, the investigators propose to explore impairment in pre/post synaptic function in the cardiac left ventricle.

详细描述

Overall, these studies will help us answer whether the circadian system predispose individuals to increased CV disease risk - particularly around the vulnerable morning period, and whether these risks differ with obesity. The results will serve as a foundation for clinical trials of appropriately timed dosing of medications targeting aspects of the CV system that increase effectiveness while decreasing side effects, and may have particular relevance to management of CV risk in people with obesity.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
25 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Ages 25-65
  • Lean and overweight (BMI 18.5-40kg/m2)
  • Habitually sedentary

排除标准

  • History of smoking/tobacco use
  • Moderate to severe obstructive sleep apnea.
  • Prior shift work within 6 months prior to the study.
  • Prescription medications
  • Drugs of abuse
  • Acute, chronic, or debilitating medical condition (including diabetes, hypertension, and metabolic syndrome)

结局指标

主要结局

Blood Pressure

时间窗: 5 Days

Beat-by-beat and ambulatory blood pressure measurements.

次要结局

  • Epinephrine(5 days)
  • Cortisol(5 days)
  • Coronary Microvascular Blood Flux(3 days)
  • Flow Mediated Dilation (FMD)(5 days)
  • Heart Rate(5 Days)
  • Norepinephrine(5 days)
  • Epinephrine(5 days)
  • Cortisol(5 days)
  • Flow Mediated Dilation (FMD)(5 days)
  • Coronary Microvascular Blood Flux(3 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Steven A. Shea

Director

Oregon Health and Science University

研究点 (2)

Loading locations...

相似试验

Body Weight, Sleep, and Heart Health | 临床试验